Clinical Trial Update: Fisetin to Reduce Senescence and Mobility Impairment in PAD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating whether fisetin can reduce cellular senescence and improve mobility in people with peripheral arterial disease; currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Arterial Disease

Drugs mentioned

• Fisetin (fisetin)

Snippet

Sponsor: Northwestern University | Conditions: Peripheral Arterial Disease, Aging | Phase 2 | Status: RECRUITING